Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

PALO ALTO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced financial results for the three month period ended June 30, 2007.

Net revenue for second quarter of 2007 was $108,850, a 22% increase compared to $89,319 in the second quarter of 2006. Net loss applicable to common stock for the second quarter of 2007 was $2,520,674, or $(0.05) per basic and diluted share, compared to a net loss of $1,686,164, or $(0.03) per basic and diluted share, in the second quarter of 2006. Year-over-year net loss increased by $834,510, or $(0.02) per basic and diluted share, primarily as a result of increased research and development expenses associated with clinical development and stock-based compensation expense Net loss during the most recent quarter was also affected by dividends and accretion associated with the Company's redeemable convertible preferred stock.

"We have made significant advancements in both our pharmaceutical and dermaceutical programs, and are pleased to have hit several milestones during the most recent quarter," stated Belinda Tsao-Nivaggioli, Avicena's Chief Executive Officer. "In terms of our clinical programs, we are extremely encouraged by the pace of enrollment in our NIH-funded Phase III Parkinson's disease trial, and received positive feedback from the FDA for advancing our Huntington's disease program into a Phase III trial in early 2008. Overall we are very pleased with how both our neurology and dermaceutical programs are progressing."

Research and development expenses for the second quarter of 2007 were $826,233, up from $175,191 in the second quarter of 2006 primarily based on clinical development costs to support late-stage clinical programs, including the supply of drugs and placebo for ongoing trials, as well as patent-related legal expenses. Selli
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
... Feb. 11 Replikins Ltd. announced that the,quantitative ... structure,predicts that the current H5N1 cycle is over. ... and high mortality characteristics,are expected to subside - ... or,another influenza virus strain begins., 140,000 virus ...
... Cryo-Cell,International, Inc. (OTC Bulletin Board Symbol: CCEL) (the ... family cord blood banks, today,announced results for fiscal ... ended November 30, 2007 were,approximately $17.5 million, up ... ended November 30, 2006. The Company reported a ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 3Cryo-Cell International, Inc. Reports Results for Fiscal 2007 4Cryo-Cell International, Inc. Reports Results for Fiscal 2007 5Cryo-Cell International, Inc. Reports Results for Fiscal 2007 6
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... NJIT this week for an all-day public forum on ... Agency (EPA) to dredge toxic sediment from an eight-mile ... has called the plan, which proposes removing 4.3 million ... the riverbed, one of the largest cleanups in the ... disposed off-site. , "We need to ensure the future ...
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
Breaking Biology News(10 mins):Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... Imagine a polka-dotted postage stamp that can sniff out poisonous ... reported in the Sept. 13 issue of the journal ... University of Illinois have developed an artificial nose for the ... fast and inexpensive and works by visualizing odors. ...
... The master gene that causes blood stem cells to ... identified by scientists, in a study published in Nature ... boost the body,s production of these frontline tumour-killing cells, creating ... ,knocked out, the gene in question, known as E4bp4, in ...
... a widespread and expensive social problem. Recent research ... interaction between genetic inheritance and environment for development ... common knowledge that childhood maltreatment often causes psychiatric ... (e.g. aggression or antisocial behaviour) later in life. ...
Cached Biology News:Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Master gene that switches on disease-fighting cells identified by scientists 2Master gene that switches on disease-fighting cells identified by scientists 3Are the monoamines involved in shaping conduct disorders? 2Are the monoamines involved in shaping conduct disorders? 3Are the monoamines involved in shaping conduct disorders? 4Are the monoamines involved in shaping conduct disorders? 5Are the monoamines involved in shaping conduct disorders? 6
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... large numbers of samples may be carried out ... operator attention. System control and data processing ... 4900. The elegant, powerful and very easy ... Windows 98 and 2000., The supplied detector is ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
Biology Products: